In QuotedData’s morning briefing 28 April 2022:
- Downing Renewables Infrastructure (DORE) says that recent additions to the portfolio (the Swedish wind asset and the Swedish hydropower portfolios) are expected to add around 3.7p to its NAV. These increases are due to operational and capital efficiencies as a result of the integration of the assets, particularly the hydropower assets, into the Downing Hydro AB (DHAB) platform, and also the more attractive pricing available for individual sites or small portfolios when compared to larger facilities.
- Syncona (SYNC) is investing £15m into OMass Therapeutic’s £75.5m Series B financing. OMass, an Oxford University spin out, is developing small molecule drugs to treat rare diseases and immunological conditions. The company has a unique approach to the way it finds new medicines. It uses its proprietary drug discovery platform, OdyssION™, to more accurately interrogate the target and how it interacts with its native ecosystem. These observations provide potentially critical information that can increase the chances of finding highly effective small molecule medicines that will be successful in clinical trials. Based on this deal, Syncona’s original investment has been written up in value by 32%. It will have a 31% stake in the company.
We also have results from Aquila European Renewables Income, Round Hill Music, Vietnam Enterprise and Standard Life Investments Property Income Trust.